Post_template - Page 7 of 10

OncOne’s CSO Michael Thiele published a new review article on oxMIF

Our CSO, Michael Thiele has published the review article “OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases” in the Journal for Immunotherapy of Cancer. With support from OncoOne’s new SAB members, Dr. Seamas Donnelly and Dr. Robert Mitchell, Michael

OncoOne Expands Scientific Advisory Board Adding Three World-Renowned MIF and Macrophage Experts to Support Upcoming Clinical Programs

PDF Vienna, Austria – September 7, 2022 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, today announced the appointment of three new members to its scientific advisory board to accelerate the clinical development of the company’s oxidized macrophage

World Conference of Lung Cancer, August 6–9, 2022, Vienna, AT

Meet our Director Preclinical Development, Christine Landlinger at the WCLC in Vienna, Austria. Be sure to visit Christine’s e-poster on August 8 to learn more about our clinical candidate for the treatment of malignant solid tumors (e-poster EP08.01-015 – Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2022, Barcelona, ES

Our Senior Scientist Barbara Maurer will attend the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain. Barbara will present data demonstrating antitumorigenic activity and TME modulation of ON203 in patient-derived colorectal cancer tumoroids.

Theranostics World Congress, June 24–26, 2022, Wiesbaden, DE

Our Director CMC Biologics, Friedmund Bachmann will attend the 6th Theranostics World Congress in Wiesbaden, Germany. He will present a poster on ON102, our diagnostic radioimmunoconjugate targeting oxMIF.

OncoOne to attend EACR, June 20–23, 2022, Seville, ES

Meet our Director Preclinical Development, Christine Landlinger & Barbara Maurer, Senior Scientist at the EACR 2022 in Seville, Spain. Be sure to visit Barbara’s poster on ON203 to learn more about our clinical candidate for solid tumor indications.

BIO International Convention, June 13–16, 2022, San Diego, CA, US

OncoOne’s CEO, Randolf Kerschbaumer will be present at the BIO2022. Randolf will give a corporate presentation on June 15 at 4:45 PM PDT on our innovative oxMIF-targeting pipeline in oncology & immunology.

Targeted Radiopharmaceuticals Summit Europe, December 6-8, 2022, Amsterdam, NL

Join our Director CMC Biologics, Friedmund Bachmann at the 4th TRPEurope Summit in Amsterdam. Conference participants will have the opportunity to meet Friedmund during a presentation examining ON102, our proprietary radioimmunoconjugate designed to provide a non-invasive approach for diagnostic applications.

World Congress on Inflammation, June 5–8, 2022, Rome, IT

Meet our Director Preclinical Development & Project Lead Inflammation, Christine Landlinger & Maroua Ferhat, Research Scientist at the WCI22 in Rome. Be sure to visit Christine’s talk on our inflammation candidate ON104 to learn more.

PEGS Boston, May 2–6, 2022, Boston, MA, US

Our CSO, Michael Thiele will be leading a session entitled “A New Immunotherapy Target: Co-Development of a Therapeutic Antibody and a Radioimmune Diagnostic Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” at the PEGS, Boston, US.